Pooled umbilical cord blood as a possible universal donor for marrow reconstitution and use in nuclear accidents

Ende, Norman; Lu, Shan; Alcid, Mark G.; Chen, Ruifeng; Mack, Richard

doi:10.1016/s0024-3205(01)01245-0

Cited by 19 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, analysis of human UCB samples, used as control, showed that a percentage of MNC ranging from a low of 0,5% to a high of 2% were CD34 positive, in accordance with data reported by other authors (D'arena et al, 1996;Belvedere et al, 1999;Ende et al, 2001) ( Figure 1).…”

Section: Resultssupporting

confidence: 90%

Monoclonal antibodies against human CD34 antigens do not cross-react with ovine umbilical cord blood cells

Bonelli

Nicolussi

Manetti

et al. 2010

Italian Journal of Animal Science

View full text Add to dashboard Cite

CD34 is a cell surface glycoprotein expressed by hematopoietic progenitors and endothelial cells. It is widely used in the clinic for isolation of human hematopoietic stem cells. In recent years large animals are gaining increasing importance in biomedical research for the study and therapy of human diseases. Sheep has proved to be an useful experimental model for preclinical trials in transplantation procedures. Unfortunately, the lack of specie-specific monoclonal antibodies (MABS) recognizing hemopoietic progenitor cells hampers the use of this animal in experimental hematology. The aim of this paper was to determine whether commercial monoclonal antibodies specific for human CD34 molecule could cross-react with hematopoietic progenitor cells (HPC) present in sheep umbilical cord blood (UCB). Six antihuman CD34 MABS, recognizing the three different epitope classes, were tested in flow cytometry on purified mononuclear cells (MNC) isolated from cord blood of both species. None of the MABS used in this trial seemed to be able to identify HPC from sheep UCB. These data suggest that the panel of monoclonal antibodies used for cross reactivity detection has to be expanded with recently produced reagents. Further studies should be directed towards the production of ovine specific anti CD34 MABS

show abstract

Section: Resultssupporting

confidence: 90%

Monoclonal antibodies against human CD34 antigens do not cross-react with ovine umbilical cord blood cells

Bonelli

Nicolussi

Manetti

et al. 2010

Italian Journal of Animal Science

View full text Add to dashboard Cite

show abstract

“…+ cells in umbilical cord blood (the main effector of CIK cells) amplified more than 900 times, and CD3 + CD8 + T cells increased significantly, CD3 + CD16 + CD56 + cells increased in the same time, the results showed that umbilical cord blood can produce CIK cells and amplify potential is extremely strong, the killing activity of amplified CIK cells is also higher than peripheral blood CIK cells [10]- [13]. Comprehensive the above research results, that is derived from umbilical cord blood CIK cells is more suitable for clinical treatment.…”

Section: Cd56mentioning

confidence: 99%

CIK Cell Therapy for Solid Tumor

Zhang¹,

Yao²,

Fu³

2014

Nano BioMed ENG

View full text Add to dashboard Cite

In recent years, the clinical trials on applying cytokine induced killer (CIK) cells to solid tumor therapy have been launched worldwide. CIK cells are a heterogeneous subset of ex-vivo expanded T lymphocytes, they present a mixed T-NK phenotype and are endowed with a MHC-unrestricted antitumor activity, which have showed great advantages in clinical treatment compared with other adoptive immunity therapies, therefore, they are more and more widely used in adoptive immunotherapy of tumors. CIK cells can be used alone or in combination with surgery radiotherapy and chemotherapy for comprehensive treatment. In the present article, we keep a track of research progress both home and abroad, review the main functional characteristics of CIK cells, briefly introduce the source phenotype activation and amplification of the CIK cells, and summarize their targeting and anti-tumor mechanisms new techniques and methods and current status of international clinical trials from several aspects.

show abstract

“…Gilmore and colleagues estimated the number of stem cells present in an average UCB unit to represent only around 5% of the optimal dose required for adult hematopoietic transplantation [59]. Therefore, these cells have to be expanded ex vivo, pooled or cryopreserved [60,61]. UCB contains a heterogeneous population of stem cells expressing a range of surface markers including CD7, CD34, CD38, CD90 and CD133 [62,63].…”

Section: Umbilical Cord Blood Stem Cellsmentioning

confidence: 99%

Promising New Sources for Pluripotent Stem Cells

Leeb

Jurga²,

McGuckin³

et al. 2009

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Recent findings have placed stem cell research at the forefront of biomedical sciences. Basic research on embryonic stem cells (ESCs) has contributed to our knowledge about the developmental potential and plasticity of stem cells. Furthermore, it has raised hope to use these cells as potential source for regenerative medicine and tissue replacement after injury or disease. Unfortunately, ESCs can also form tumors and they are ethically controversial because they originate from human embryos. This review summarizes findings and therapeutic applications of ESCs and their alternatives: adult stem cells and iPS cells.

show abstract

Pooled umbilical cord blood as a possible universal donor for marrow reconstitution and use in nuclear accidents

Cited by 19 publications

References 0 publications

Monoclonal antibodies against human CD34 antigens do not cross-react with ovine umbilical cord blood cells

Monoclonal antibodies against human CD34 antigens do not cross-react with ovine umbilical cord blood cells

CIK Cell Therapy for Solid Tumor

Promising New Sources for Pluripotent Stem Cells

Contact Info

Product

Resources

About